Skip to main content

Table 5 SVR12 values for observational study regimens with and without RBV in patients who were (i) cirrhotic or non-cirrhotic a, (ii) treatment-experienced or -naïve, or (iii) HIV-positive or -negative

From: Effectiveness of current and future regimens for treating genotype 3 hepatitis C virus infection: a large-scale systematic review

Regimen SVR12% [95% CI]
Cirrhotic Non-cirrhotic Treatment-experienced Treatment-naïve HIV-positive HIV-negative
DCV + SOF containing regimens
 DCV + SOF +RBV 77.3
[70.9, 83.2]
n = 186
83.3
[41.4, 100.0]
n = 6
74.4
[66.7, 81.6]
n = 139
100.0
[86.1, 100.0]
n = 12
100.0
[73.9, 100.0]
n = 6
NR
−RBV 85.4
[79.7, 90.3]
n = 215
98.1 [92.2, 100.0]
n = 54
81.1
[65.3, 93.5]
n = 35
90.5
[73.4, 99.8]
n = 21
97.7
[82.5, 100.0]
n = 20
NR
±RBV 84.8
[33.3, 100.0]b
n = 5
NR 100.0
[73.2, 100.0]b
n = 6
NR NR 90.9
[65.0, 100.0]b
n = 11
LDV containing regimens
 LDV + SOF +RBV 64.9
[52.0, 76.8]
n = 57
NR 70.9
[54.0, 86.0]
n = 63
NR NR NR
−RBV 40.0
[1.8, 86.2]
n = 5
NR 28.6
[1.0, 68.2]
n = 7
NR NR NR
SOF containing regimens
 SOF +RBV 49.3
[40.8, 57.7]
n = 144
81.9
[74.7, 88.2]
n = 138
60.5
[50.2, 70.4]
n = 105
74.3
[66.4, 81.5]
n = 144
100.0
[30.3, 100.0]
n = 2
NR
−RBV NR NR NR NR NR NR
 SOF ± Peg-IFN +RBV 90.9
[74.5, 99.8]
n = 22
NR 91.7
[67.6, 100.0]
n = 12
NR NR NR
−RBV NR NR NR NR NR NR
Peg-IFN containing regimens
 Peg-IFN +RBV 63.9
[60.0, 67.7]
n = 713
77.8
[74.8, 80.7]
n = 845
49.4
[43.1, 55.7]
n = 257
63.3
[62.6, 64.1]
n = 16,031
66.4
[63.1, 69.6]
n = 874
63.7
[62.8, 64.6]
n = 11,995
−RBV NR NR NR NR NR NR
 Peg-IFN + SOF +RBV 100.0
[30.3, 100.0]
n = 2
NR NR NR NR NR
−RBV NR NR NR NR NR NR
  1. DCV daclatasvir, IFN interferon, LDV ledipasvir, NR not reported, RBV ribavirin, r ritonavir, SOF sofosbuvir, SVR12 sustained virological response at 12 weeks
  2. aIn this analysis, cohorts were considered non-cirrhotic if 0% of patients were cirrhotic
  3. bData from study(s) in which stratification by RBV use was not recorded